GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Advanced Biomed ADVB · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.05

+3.54%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$4,112

FY2021FY2026

Net income

$6.7m

FY2021FY2026

Free cash flow

−$62,740

FY2021FY2026

Shareholders' equity

$12.3m

FY2021FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021
Revenue$4,112—————
Gross profit—−$10,711−$12,550−$11,890−$4,477−$2,031
Research and development—$28,341$880,193$45,029$1.6m$1.7m
Operating income−$200,861−$94,112−$2.5m−$99,984−$2.4m−$1.8m
Net income$6.7m−$101,524−$2.8m−$121,521−$4.0m−$1.8m
Diluted earnings per share4.04-0.09-2.57-0.11-3.72-1.11

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Total assets$13.8m$6.5m$4.5m$4.6m$6.7m$1.0m
Cash and short-term investments$385,535$2.9m$2.6m$2.6m$4.8m$65,922
Total liabilities$1.5m$3.0m$2.8m$3.3m$3.2m$30,131
Debt$33,845$1.3m$128,657$242,326$476,827$7,209
Shareholders' equity$12.3m$3.5m$1.7m$1.3m$3.5m$976,242
Shares outstanding2m1m1m1m1m2m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021
Cash from operations−$62,735−$181,464−$2.1m−$3.0m−$741,450−$473,975
Capital spending−$5−$985−$74,110−$212,523−$1.3m−$25,442
Free cash flow−$62,740−$182,449−$2.2m−$3.2m−$2.1m−$499,417

Latest quarters

By quarter end

Sept 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$4,037——$17,200————
Gross profit—−$294−$466−$2,085—−$680—−$3,162
Operating income$855,667−$519,836−$12,778−$523,914−$1.2m−$762,739−$280,064−$520,027
Net income−$429,969−$488,942$220,947−$386,901−$701,600−$1.4m−$907,904−$265,580
Diluted earnings per share-0.26-0.300.20-0.36-0.65-1.28-0.84-0.25
Cash from operations—————−$3.0m——
Total assets$13.8m$10.6m$345,338$204,835—$8.3m$4.5m$4.5m
Cash and short-term investments$385,535$2.6m$82,897$87,161—$156,135—$2.6m
Debt$33,845$701,626$19,661$77,411—$142,524—$1.3m
Shareholders' equity$12.3m$9.2m$301,766$98,566—$4.1m$619,032$1.1m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income26.2%-35.8%—

Valuation history

At each fiscal year end

FY2026FY2025
Price to earnings0.5-39.7

Share price return

Finished calendar years

2025
Return-77%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 20 Feb 2026

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.